0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Ophthalmic Molecular Genetics |

Phenotypic Variability Due to a Novel Glu292Lys Variation in Exon 8 of the BEST1 Gene Causing Best Macular Dystrophy FREE

Elliott H. Sohn, MD; Peter J. Francis, MD, PhD; Jacque L. Duncan, MD; Richard G. Weleber, MD; David A. Saperstein, MD; Donald F. Farrell, MD; Edwin M. Stone, MD, PhD
[+] Author Affiliations

Author Affiliations: Doheny Eye Institute and Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles (Dr Sohn); Departments of Ophthalmology (Drs Sohn) and Neurology (Dr Farrell), University of Washington, Seattle; Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health & Science University, Portland (Drs Francis and Weleber); Department of Ophthalmology, University of California San Francisco, San Francisco (Dr Duncan); Vitreoretinal Associates, Seattle (Dr Saperstein); Department of Ophthalmology and Visual Sciences and the Howard Hughes Medical Institute, University of Iowa, Iowa City (Dr Stone).


Section Editor: Janey L. Wiggs, MD, PhD

More Author Information
Arch Ophthalmol. 2009;127(7):913-920. doi:10.1001/archophthalmol.2009.148.
Text Size: A A A
Published online

Objective  To study the phenotypic characteristics of patients with a novel p.E292K mutation in BEST1.

Methods  Affected individuals underwent ophthalmic examination and testing that included photography, autofluorescence, optical coherence tomography, and electrophysiological testing. Their DNA was analyzed for BEST1mutations.

Results  Five patients aged 5 to 59 years who expressed the p.E292K mutation in BEST1were identified in 3 families. Electro-oculographic light-rise was subnormal in all probands and carriers. Carriers had normal findings from fundus examination, multifocal electroretinography, and visual acuity, and were emmetropic or myopic. Only probands had hyperopia and fundus findings typical of Best macular dystrophy. Optical coherence tomography of vitelliform lesions demonstrated retinal pigment epithelium elevation without subretinal fluid; atrophic lesions exhibited disruption of the hyperreflective outer retina–retinal pigment epithelium complex. Intense hyperautofluorescence correlated with the vitelliform lesion.

Conclusions  Patients with the Glu292Lys variation in BEST1exhibit intrafamilial and interfamilial phenotypic variability. A disproportionate fraction (26%) of Best disease–causing mutations occurs in exon 8, suggesting that the portion of protein encoded by this exon (amino acids 290-316) may be especially important to bestrophin's function. Relatively good visual acuity with vitelliform lesions can be explained by preservation of the outer retina, demonstrated by optical coherence tomography.

Clinical Relevance  A novel mutation in this region of BEST1carries implications for disease pathogenesis.

Figures in this Article

Best macular dystrophy (BMD) is an autosomal dominant condition caused by mutations in the BEST1gene (OMIM 607854).1,2 Mutations in this gene result in a defective protein product, bestrophin, that localizes to the basolateral membrane of the retinal pigment epithelium (RPE)3 and has been associated with conductance abnormalities in a family of chloride channels4,5 and voltage-gated calcium channels.68 These alterations may account for the diminished light peak to dark trough ratio (Arden ratio typically ≤1.5) of the electro-oculogram (EOG) characteristic of BMD; full-field electroretinography (ffERG) findings are typically normal.9,10

The fundus findings associated with BEST1mutations are quite varied and include a normal fundus appearance with an EOG that shows abnormalities; vitelliform lesions with a “sunny-side–up” egg yolk appearance in the central macula; a “pseudohypopyon” in which the yellow material gravitates inferiorly in the sub-RPE space; a “scrambled-egg” appearance characterized by yellowish subretinal deposits admixed with patches of hyperpigmentation and atrophy of the RPE; geographic atrophy; nodular subretinal gliosis centered on fixation; and, rarely, choroidal neovascularization.11 Visual acuity is often preserved in at least 1 eye throughout life, with more substantial visual loss occurring when BMD is complicated by choroidal neovascularization1214 or extensive geographic atrophy.

Newer diagnostic techniques have refined our understanding of the anatomy of the macular lesions seen in patients with Best disease.1520 For example, one of the first optical coherence tomographic (OCT) studies in these patients showed that the vitelliform material may lie between the outer retina and the RPE.21 Increased fluorescence of vitelliform fundus lesions on fundus autofluorescence (AF)22,23 images may be due to enhanced accumulation of fluorophores such as A2E.18

Although the precise structure of the protein has yet to be elucidated, it has been hypothesized that bestrophin has 4 transmembrane domains with amino and carboxyl terminals located in the cytoplasm. Most of the described BEST1mutations causing BMD have been missense mutations,1,2,22,2440 and a disproportionate fraction of these mutations occurs in exon 8, suggesting that the portion of the protein encoded by this exon may be especially critical to its function. At the time of this writing, the Carver Nonprofit Genetic Testing Laboratory has observed 155 instances of 84 different BEST1mutations in probands affected with Best disease, and 22 of these mutations (26%) lie within exon 8 (Tyler Kinnick, PhD, and E.M.S., unpublished data, 2008). Additional evidence of the functional importance of this portion of the protein is that exon 8 is highly conserved among the BEST1orthologs of Caenorhabditis elegans, Drosophila melanogaster, and mice.2 In addition, a functional analysis of an exon 8 variant (Q293H) in human embryonic kidney cells revealed a severe reduction of chloride current that behaved in a dominant negative manner.27

In the present study, we identified individuals from 3 apparently unrelated families with a missense mutation in BEST1causing a change at position 292 of glutamic acid to lysine. Clinical characterization including AF, OCT, and ffERG and multifocal ERG (mfERG) of these individuals demonstrates highly variable expression between individuals as well as intrafamilial variability with nonpenetrance of fundus findings in 2 consecutive generations.

Three probands (aged 5-59 years) from 3 unrelated families were identified by characteristic fundus findings and abnormal Arden ratio on EOG. Family members of the 5-year-old boy were also examined, and electrophysiology was performed. After informed consent was obtained, blood samples were taken for DNA extraction, and subsequent mutation screening of BEST1was performed at the John and Marcia Carver Nonprofit Genetic Testing Laboratory in Iowa City, Iowa. The protocol adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review boards of the institutions involved.

A full medical history was taken and ophthalmic examination was performed. Patients underwent digital color fundus photography. The AF images of the 54-year-old subject were obtained using a TopCon 50EX digital fundus camera equipped with AF filters purchased from Ophthalmic Imaging Systems (Sacramento, California), similar to a system previously described.41,42 The OCT images were obtained using the Stratus III (Stratus OCT 4.0.2 software; Zeiss Instruments, Dublin, California). Electrophysiological assessment included ffERG and EOG, using recording methods laid out by International Society for Clinical Electrophysiology of Vision (ISCEV) standards and recommendations for electroretinography43,44 and EOG.43 The mfERG was performed in 4 cases according to guidelines that have been described elsewhere.41,45

Mutation analysis revealed a missense variation resulting in a change of glutamic acid to lysine at amino acid position 292 in BEST1in all probands and obligate carriers. Genotyping of 4 informative short tandem repeat polymorphisms at the BEST1locus revealed a distinctly different disease-associated haplotype in family 1, strongly suggesting that the Glu292Lys mutation in that family occurred independently (data not shown). Summaries of the clinical findings for patients in this study are shown in the Table.

Table Graphic Jump LocationTable. Summary of Clinical Findings in 3 Families of Patients With the Glu292Lys BEST1Variation
PROBAND 1 AND FAMILY MEMBERS

The parents of a 5-year-old boy noted intermittent convergent strabismus in the child for 8 weeks. Refractive error of +5.25 diopter spheres OU resulted in orthophoria with best-corrected visual acuity of 20/40 OU. His irides were green. Anterior segment examination, including anterior chamber depth, was within normal limits. Fundus examination revealed bilateral central vitelliform lesions (Figure 1, A and B). The ffERG was normal and EOG revealed Arden ratios of 1.1 OD and 1.4 OS. The OCT showed a discrete elevation of RPE and widening of the hyperreflective signal from the outer retina–RPE complex (Figure 1, C and D).

Place holder to copy figure label and caption
Figure 1.

Fundus photographic and ocular coherence tomographic (OCT) images of proband 1. A and B, Fundus shows well-demarcated vitelliform lesions in the central macula. C and D, Corresponding OCT sections show elevation at the level of the retinal pigment epithelium, with preservation of the outer retinal layer.

Graphic Jump Location

The asymptomatic mother, who is of Scandinavian, Irish, and German descent, and the father, who is of French, German, and Norwegian descent, both had visual acuity of 20/20 without correction and normal fundus examination. However, EOG of the 30-year-old mother revealed Arden ratios of 1.2 OD and 1.3 OS. Her ffERG and mfERG scans showed no abnormalities. Genetic testing of the mother revealed that she had the same mutation in BEST1Glu292Lys as her son.

This led to examination and testing of other family members (Figure 2) to further characterize the inheritance pattern. The proband's maternal grandfather, aged 57 years, was asymptomatic, with best-corrected visual acuity of 20/20. He had Arden ratios of 1.3 OU, and his ffERG and mfERG showed no abnormalities. Manifest refraction was −0.75 + 1.00@055 OD, −1.00 + 1.00@180 OS. His intraocular pressure was 14 mm Hg OU, and irides were hazel. His anterior chamber depth was normal. The crystalline lens was clear. Posterior segment examination revealed rare RPE changes but no vitelliform lesion or atrophy.

Place holder to copy figure label and caption
Figure 2.

Pedigree of proband 1 (indicated by shaded box) demonstrates lack of penetrant fundus findings and hyperopia in carriers. Wt indicates wild type; yo, years old.

Graphic Jump Location

In addition, EOG testing of the above proband and asymptomatic carriers revealed prolonged light-peak slow oscillation, consistent with previously described findings in humans46 and animals47 with BMD.

PROBAND 2

The patient is a 54-year-old man of East Indian descent who was referred for reduced vision in the right eye for the past 10 years. His family history was unremarkable for similar vision problems. His best-corrected visual acuity was 20/200 (eccentric) OD and 20/20 OS. His refractive error was +2.25 + 0.75@180 OD, +1.75 + 0.75@165 OS. His intraocular pressure was 12 mm Hg OD and 14 mm Hg OS.

Anterior segment examination revealed brown irides and normal anterior chamber depth. Fundus examination revealed a central circumscribed area of atrophy in the right eye and a vitelliform lesion in the left eye (Figure 3, A and B). Both eyes exhibited deep fleck-like changes nasal to the disc and along the temporal arcades. The AF images of the right eye (Figure 3E) showed a central macular hypoautofluorescent lesion that corresponded to the area of atrophy on fundus examination with patches of increased AF, especially in the periphery of the lesion. Autofluorescence of both eyes allowed better visualization of the fleck-like lesions around the disc and arcades, exhibiting mixed hyperautofluorescence and hypoautofluorescence that was confluent in many areas. The AF images of the left eye (Figure 3F) showed a central area of homogenously increased autofluorescence corresponding to the vitelliform lesion. Optical coherence tomographic imaging (Figure 3C) revealed increased backscatter from the underlying sclera in the region of RPE atrophy with some irregular disruptions in the outer retina–RPE complex at the edges of the atrophic lesion in the right eye; OCT images in the left eye (Figure 3D) showed discrete elevation of the RPE without discontinuity of the hyperreflective outer retina–RPE complex.

Place holder to copy figure label and caption
Figure 3.

Fundus photographic, ocular coherence tomographic (OCT), and autofluorescence (AF) images of proband 2. A and B, Fundus photographs demonstrate central atrophy of the right eye and a vitelliform lesion of the left eye. Both exhibit fleck-like changes nasal to the disc and around the arcades. C, OCT of the right eye reflects retinal pigment epithelium (RPE) atrophy, with disruption in the outer retina–RPE complex. D, OCT of the left eye shows discrete RPE elevation. E, AF of the right eye demonstrates a central hypoautofluorescent lesion. Fleck-like lesions around the disc and arcades reveal mixed hyperautofluorescence and hypoautofluorescence in both eyes. F, AF of the left eye shows central hyperautofluorescence corresponding to the vitelliform lesion.

Graphic Jump Location

Electrophysiological assessment revealed an Arden ratio of 1.5 OD and 1.3 OS. The ffERG was normal. Fixation was not stable enough to permit reliable mfERG recording using a pupil camera in the right eye, but mfERG of the left eye demonstrated reduced responses from the central 1° to 5° OS (Figure 4) with relative preservation of the response amplitude and timing from the surrounding macula.

Place holder to copy figure label and caption
Figure 4.

Multifocal electroretinography of the left eye of proband 2 demonstrates reduced responses from the central 1° to 5° OS with relative preservation of the response amplitude and timing from the surrounding macula.

Graphic Jump Location
PROBAND 3

This 59-year-old woman of Norwegian and Jewish descent with green irides was found on routine examination 22 years earlier to have fundus findings suspicious for BMD. Two sisters and a nephew are thought to have BMD, and while her mother had vision problems, no diagnosis had been made at the time of her death. Ocular history was significant for hyperopia and laser peripheral iridotomy in both eyes for occludable angles. Medical history was significant for well-controlled diabetes mellitus type 2, polymyalgia rheumatica, reflux disease, and osteoarthritis.

Visual acuity was 20/70 OD with +1.25 + 0.50@170 and 20/50 OS with +1.00 + 0.25@010. On biomicroscopy, the laser peripheral iridotomies were patent and there was mild nuclear sclerosis in both eyes. Fundus examination revealed bilateral central atrophy with few drusen in the midperiphery (Figure 5, A and B). Corresponding to the area of atrophy seen on examination, OCT revealed attenuation of the outer retina and hyperreflectivity of the RPE with increased signal posterior to the RPE (Figure 5, C and D).

Place holder to copy figure label and caption
Figure 5.

Fundus photographic and optical coherence tomographic (OCT) images of proband 3. A and B, Fundus reveals bilateral central atrophy with few drusen in the midperiphery of both eyes. C and D, OCT indicates areas of atrophy seen with increased signal posterior to the retinal pigment epithelium and attenuation of the outer retina.

Graphic Jump Location

The Arden ratio was 1.2 OD and 1.1 OS. Her ffERG showed no abnormalities; mfERG (Figure 6) exhibited attenuation of amplitude and latency delay that was most prominent in the central macula with relative sparing of the peripheral macula.

Place holder to copy figure label and caption
Figure 6.

Multifocal electroretinography of proband 3 demonstrates attenuation of amplitude and latency delay most prominent in the central macula, with relative sparing of the periphery.

Graphic Jump Location

The BEST1gene, together with BEST2, BEST3, and BEST4, are part of a closely related gene family characterized by several transmembrane-spanning domains and an invariant arginine-phenylalanine-proline motif. These 4 human genes are believed to be orthologous to a gene in C elegansthat shares a highly conserved 26–amino acid sequence beginning at position 289.48 Three lines of evidence support the idea that the novel bestrophin variation reported here is disease causing. First, the glutamic acid residue normally present at position 292 is highly conserved evolutionarily. Second, glutamic acid is negatively charged at neutral pH, while the lysine residue found in affected individuals is positively charged. This is the most extreme charge difference possible for a point mutation. Finally, presence of the mutation in 3 unrelated families with different bestrophin haplotypes suggests that the variation arose more than once. This makes it very likely that Glu292Lys is the disease-causing variation in the gene and not simply a non–disease-causing polymorphism in linkage disequilibrium with a true disease-causing mutation nearby. Mutations are common in the region of the human BEST1gene encoding amino acids 290 through 316, suggesting that this portion of the protein is critical to its function.

In the present study, we performed a detailed clinical and electrophysiological evaluation of 5 subjects from 3 unrelated families who share a previously undescribed missense mutation in BEST1, a change from glutamic acid to lysine at amino acid position 292. We observed variable expressivity in our cohort of patients. Only the reduced light peak on the EOG was completely penetrant. Hyperopia was also found in all probands but was distinctly absent in carriers. Though it is tempting to attribute this to reduced axial length from the elevated fundus lesion, hyperopia was also found in our patients with flat atrophic retinas, as demonstrated on OCT. Moreover, similar degrees of hyperopia were seen in proband 2 despite atrophy in one eye and a vitelliform lesion in the other. Hyperopia is a common finding in patients with BMD22,49 and is found in other conditions caused by mutations in BEST1such as autosomal dominant vitreoretinochoroidopathy50 and autosomal recessive bestrophinopathy.51 Findings of hyperopia in probands may be related to genetic modifiers such as microphthalmia-associated transcription factor (MITF).52,53 Interactions between MITFand BEST1have not been fully explored. While it is unclear whether our probands were hyperopic before the development of lesions, it would be interesting to compare the prevalence of hyperopia in probands and carriers and determine whether hyperopia is a predictive factor for developing vitelliform lesions. Such a finding would have implications for prognosis and counseling of patients and families. The lack of hyperopia among carriers in our study could indicate a favorable prognostic sign in patients with this mutation.

While proband 1 had mildly diminished visual acuity despite the presence of vitelliform lesions, both his mother and his 57-year-old maternal grandfather had relatively normal fundi despite diminished EOG and the presence of the Glu292Lys variation. In addition to emmetropia, normal visual acuity, and lack of fundus lesions, both carriers also had normal ffERG and mfERG responses. This appears to be the first demonstration of nonpenetrant fundus findings in 2 consecutive generations with a confirmed BEST1mutation. Given the early age at which large vitelliform lesions are typically observed, it seems more likely that the variable clinical findings among patients carrying the same BEST1variation are due to modifying genes rather than environmental factors.

The results of OCT and AF performed in our patients allow us to speculate on the nature of the vitelliform lesion, for which histopathology in a human eye has not been performed. Models of BEST1mutations in dogs54 and mice47 are not adequate for this purpose, as these animals do not develop typical vitelliform lesions. Human eyes with the scrambled egg appearance have abnormally high amounts of lipofuscin.17 Studies in elderly individuals homozygous or heterozygous for mutations in BEST1have demonstrated modestly elevated levels of A2E compared with controls.18 However, it is unknown whether A2E is a by-product of the latter stages of disease or whether other components of lipofuscin contribute to the hyperautofluorescent appearance in early stages. Intense hyperautofluorescence corresponding to the vitelliform lesion was seen in the left eye of proband 2, but a circumscribed patch of decreased AF corresponded to the atrophic lesion with speckled increased AF. In light of histopathological studies of late BMD,15,16 this loss of AF is likely due to irregularities in the RPE cell monolayer with secondary loss of photoreceptor outer segment turnover correlating with the poor level of vision in this eye. Relatively preserved visual acuity was seen in probands 1 and 2, with vitelliform lesions causing RPE elevations. Notably, OCT revealed no evidence of serous detachment in our patients, as recently reported in patients with BMD studied with spectral domain OCT.55 This contrasts with other studies of autofluorescent vitelliform lesions that showed fluid between the RPE and outer retina.21,56 One hypothesis accounting for our findings is that mutated bestrophin in RPE, which likely contains lipofuscin in the vitelliform stage, causes impaired transport of fluid to the choroid, resulting in separation of the RPE from the choroid. Progression causes defective pumping of subretinal fluid to the RPE, resulting in the detachment of the outer retina from RPE that was shown in previous studies of eyes with more advanced disease.

Patients with Glu292Lys variation in BEST1exhibit intrafamilial and interfamilial phenotypic variability. Thus, it is important for clinicians to realize that identification of the variation by genetic testing does not always portend the eventual development of macular disease. Our findings support the idea that the portion of the protein consisting of amino acids 290 through 316 may be critical to the function of bestrophin. Relatively good visual acuity with vitelliform lesions can be explained by preservation of the outer retina demonstrated by OCT.

Correspondence: Elliott H. Sohn, MD, Doheny Eye Institute, 1450 San Pablo St, Ste 3608, Los Angeles, CA 90033 (elliott.sohn@gmail.com).

Submitted for Publication: December 6, 2008; final revision received January 23, 2009; accepted February 3, 2009.

Financial Disclosure: None reported.

Funding/Support: This study was supported in part by Research to Prevent Blindness (Drs Francis, Duncan, and Weleber); Foundation Fighting Blindness (Drs Sohn, Francis, Duncan, and Weleber); National Eye Institute grant EY002162, That Man May See, Inc, the Bernard A. Newcomb Macular Degeneration Fund, Hope for Vision, and the Karl Kirchgessner Foundation (Dr Duncan); the Curran Fund for Research on Best Disease (Dr Weleber); and the Howard Hughes Medical Institute (Dr Sohn).

Additional Contributions: The authors thank Karmen Trzupek, MS, CGC, Susan Clarke, MLIS, Jean Andorf, and Becky Johnston for their excellent assistance.

Petrukhin  KKoisti  MJBakall  B  et al.  Identification of the gene responsible for Best macular dystrophy. Nat Genet 1998;19 (3) 241- 247
PubMed Link to Article
Marquardt  AStöhr  HPassmore  LAKrämer  FRivera  AWeber  BH Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). Hum Mol Genet 1998;7 (9) 1517- 1525
PubMed Link to Article
Marmorstein  ADMarmorstein  LYRayborn  MWang  XHollyfield  JGPetrukhin  K Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2000;97 (23) 12758- 12763
PubMed Link to Article
Sun  HTsunenari  TYau  KWNathans  J The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A 2002;99 (6) 4008- 4013
PubMed Link to Article
Tsunenari  TSun  HWilliams  J  et al.  Structure-function analysis of the bestrophin family of anion channels. J Biol Chem 2003;278 (42) 41114- 41125
PubMed Link to Article
Marmorstein  LYWu  JMcLaughlin  P  et al.  The light peak of the electroretinogram is dependent on voltage-gated calcium channels and antagonized by bestrophin (best-1). J Gen Physiol 2006;127 (5) 577- 589
PubMed Link to Article
Rosenthal  RBakall  BKinnick  T  et al.  Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J 2006;20 (1) 178- 180
PubMed
Yu  KXiao  QCui  GLee  AHartzell  HC The best disease-linked Cl- channel hBest1 regulates Ca V 1 (L-type) Ca2+ channels via src-homology-binding domains. J Neurosci 2008;28 (22) 5660- 5670
PubMed Link to Article
Deutman  AF Electro-oculography in families with vitelliform dystrophy of the fovea: detection of the carrier state. Arch Ophthalmol 1969;81 (3) 305- 316
PubMed Link to Article
Krill  AEMorse  PAPotts  AMKlien  BA Hereditary vitelliruptive macular degeneration. Am J Ophthalmol 1966;61 (6) 1405- 1415
PubMed
Miller  SABresnick  GHChandra  SR Choroidal neovascular membrane in Best's vitelliform macular dystrophy. Am J Ophthalmol 1976;82 (2) 252- 255
PubMed
Mohler  CWFine  SL Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology 1981;88 (7) 688- 692
PubMed Link to Article
Fishman  GABaca  WAlexander  KRDerlacki  DJGlenn  AMViana  M Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology 1993;100 (11) 1665- 1670
PubMed Link to Article
Chung  MMOh  KTStreb  LMKimura  AEStone  EM Visual outcome following subretinal hemorrhage in Best disease. Retina 2001;21 (6) 575- 580
PubMed Link to Article
Frangieh  GTGreen  WRFine  SL A histopathologic study of Best's macular dystrophy. Arch Ophthalmol 1982;100 (7) 1115- 1121
PubMed Link to Article
O'Gorman  SFlaherty  WAFishman  GABerson  EL Histopathologic findings in Best's vitelliform macular dystrophy. Arch Ophthalmol 1988;106 (9) 1261- 1268
PubMed Link to Article
Weingeist  TAKobrin  JLWatzke  RC Histopathology of Best's macular dystrophy. Arch Ophthalmol 1982;100 (7) 1108- 1114
PubMed Link to Article
Bakall  BRadu  RAStanton  JB  et al.  Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res 2007;85 (1) 34- 43
PubMed Link to Article
Mullins  RFKuehn  MHFaidley  EASyed  NAStone  EM Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease. Invest Ophthalmol Vis Sci 2007;48 (7) 3372- 3380
PubMed Link to Article
Mullins  RFOh  KTHeffron  EHageman  GSStone  EM Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. Arch Ophthalmol 2005;123 (11) 1588- 1594
PubMed Link to Article
Pianta  MJAleman  TSCideciyan  AV  et al.  In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 2003;76 (2) 203- 211
PubMed Link to Article
Renner  ABTillack  HKraus  H  et al.  Late onset is common in best macular dystrophy associated with VMD2 gene mutations. Ophthalmology 2005;112 (4) 586- 592
PubMed Link to Article
von Rückmann  AFitzke  FWBird  AC In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol 1997;115 (5) 609- 615
PubMed Link to Article
Bakall  BMarknell  TIngvast  S  et al.  The mutation spectrum of the bestrophin protein: functional implications. Hum Genet 1999;104 (5) 383- 389
PubMed Link to Article
Caldwell  GMKakuk  LEGriesinger  IB  et al.  Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. Genomics 1999;58 (1) 98- 101
PubMed Link to Article
Eksandh  LBakall  BBauer  BWadelius  CAndréasson  S Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene. Ophthalmic Genet 2001;22 (2) 107- 115
PubMed Link to Article
Marchant  DYu  KBigot  K  et al.  New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. J Med Genet 2007;44 (3) e70
PubMed Link to Article
Wabbels  BPreising  MNKretschmann  UDemmler  ALorenz  B Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 2006;244 (11) 1453- 1466
PubMed Link to Article
Apushkin  MAFishman  GATaylor  CMStone  EM Novel de novo mutation in a patient with Best macular dystrophy. Arch Ophthalmol 2006;124 (6) 887- 889
PubMed Link to Article
Krämer  FMohr  NKellner  URudolph  GWeber  BH Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD). Hum Mutat 2003;22 (5) 418
PubMed Link to Article
Krämer  FWhite  KPauleikhoff  D  et al.  Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet 2000;8 (4) 286- 292
PubMed Link to Article
Li  YWang  GDong  B  et al.  A novel mutation of the VMD2 Gene in a Chinese family with best vitelliform macular dystrophy. Ann Acad Med Singapore 2006;35 (6) 408- 410
PubMed
Marchant  DGogat  KBoutboul  S  et al.  Identification of novel VMD2 gene mutations in patients with best vitelliform macular dystrophy. Hum Mutat 2001;17 (3) 235
PubMed Link to Article
Seddon  JMSharma  SChong  SHutchinson  AAllikmets  RAdelman  RA Phenotype and genotype correlations in two best families. Ophthalmology 2003;110 (9) 1724- 1731
PubMed Link to Article
Sodi  APasserini  ISimonelli  FTesta  FMenchini  UTorricelli  F A novel mutation in the VMD2 gene in an Italian family with Best maculopathy. J Fr Ophtalmol 2007;30 (6) 616- 620
PubMed Link to Article
White  KMarquardt  AWeber  BH VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies. Hum Mutat 2000;15 (4) 301- 308
PubMed Link to Article
Palomba  GRozzo  CAngius  APierrottet  COOrzalesi  NPirastu  M A novel spontaneous missense mutation in VMD2 gene is a cause of a best macular dystrophy sporadic case. Am J Ophthalmol 2000;129 (2) 260- 262
PubMed Link to Article
Schatz  PKlar  JAndréasson  SPonjavic  VDahl  N Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet 2006;27 (2) 51- 56
PubMed Link to Article
Lotery  AJMunier  FLFishman  GA  et al.  Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41 (6) 1291- 1296
PubMed
Marchant  DGogat  KDureau  P  et al.  Use of denaturing HPLC and automated sequencing to screen the VMD2 gene for mutations associated with Best's vitelliform macular dystrophy. Ophthalmic Genet 2002;23 (3) 167- 174
PubMed Link to Article
Duncan  JLZhang  YGandhi  J  et al.  High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci 2007;48 (7) 3283- 3291
PubMed Link to Article
Spaide  RF Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110 (2) 392- 399
PubMed Link to Article
Marmor  MFZrenner  EInternational Society for Clinical Electrophysiology of Vision, Standard for clinical electro-oculography. Arch Ophthalmol 1993;111 (5) 601- 604
PubMed Link to Article
Marmor  MFZrenner  EInternational Society for Clinical Electrophysiology of Vision, Standard for clinical electroretinography (1999 update). Doc Ophthalmol 1998-1999;97 (2) 143- 156
PubMed Link to Article
Marmor  MFHood  DCKeating  DKondo  MSeeliger  MWMiyake  YInternational Society for Clinical Electrophysiology of Vision, Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 2003;106 (2) 105- 115
PubMed Link to Article
Weleber  RG Fast and slow oscillations of the electro-oculogram in Best's macular dystrophy and retinitis pigmentosa. Arch Ophthalmol 1989;107 (4) 530- 537
PubMed Link to Article
Marmorstein  ADStanton  JBYocom  J  et al.  A model of best vitelliform macular dystrophy in rats. Invest Ophthalmol Vis Sci 2004;45 (10) 3733- 3739
PubMed Link to Article
Stöhr  HMarquardt  ANanda  ISchmid  MWeber  BH Three novel human VMD2-like genes are members of the evolutionary highly conserved RFP-TM family. Eur J Hum Genet 2002;10 (4) 281- 284
PubMed Link to Article
Bard  LACross  HE Genetic counseling of families with Best macular dystrophy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1975;79 (6) OP865- OP873
PubMed
Yardley  JLeroy  BPHart-Holden  N  et al.  Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci 2004;45 (10) 3683- 3689
PubMed Link to Article
Burgess  RMillar  IDLeroy  BP  et al.  Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008;82 (1) 19- 31
PubMed Link to Article
Esumi  NKachi  SCampochiaro  PAZack  DJ VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. J Biol Chem 2007;282 (3) 1838- 1850
PubMed Link to Article
Esumi  NOshima  YLi  YCampochiaro  PAZack  DJ Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 2004;279 (18) 19064- 19073
PubMed Link to Article
Guziewicz  KEZangerl  BLindauer  SJ  et al.  Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci 2007;48 (5) 1959- 1967
PubMed Link to Article
Querques  GRegenbogen  MQuijano  CDelphin  NSoubrane  GSouied  EH High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol 2008;146 (4) 501- 507
PubMed Link to Article
Spaide  RFNoble  KMorgan  AFreund  KB Vitelliform macular dystrophy. Ophthalmology 2006;113 (8) 1392- 1400
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Fundus photographic and ocular coherence tomographic (OCT) images of proband 1. A and B, Fundus shows well-demarcated vitelliform lesions in the central macula. C and D, Corresponding OCT sections show elevation at the level of the retinal pigment epithelium, with preservation of the outer retinal layer.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Pedigree of proband 1 (indicated by shaded box) demonstrates lack of penetrant fundus findings and hyperopia in carriers. Wt indicates wild type; yo, years old.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Fundus photographic, ocular coherence tomographic (OCT), and autofluorescence (AF) images of proband 2. A and B, Fundus photographs demonstrate central atrophy of the right eye and a vitelliform lesion of the left eye. Both exhibit fleck-like changes nasal to the disc and around the arcades. C, OCT of the right eye reflects retinal pigment epithelium (RPE) atrophy, with disruption in the outer retina–RPE complex. D, OCT of the left eye shows discrete RPE elevation. E, AF of the right eye demonstrates a central hypoautofluorescent lesion. Fleck-like lesions around the disc and arcades reveal mixed hyperautofluorescence and hypoautofluorescence in both eyes. F, AF of the left eye shows central hyperautofluorescence corresponding to the vitelliform lesion.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Multifocal electroretinography of the left eye of proband 2 demonstrates reduced responses from the central 1° to 5° OS with relative preservation of the response amplitude and timing from the surrounding macula.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.

Fundus photographic and optical coherence tomographic (OCT) images of proband 3. A and B, Fundus reveals bilateral central atrophy with few drusen in the midperiphery of both eyes. C and D, OCT indicates areas of atrophy seen with increased signal posterior to the retinal pigment epithelium and attenuation of the outer retina.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 6.

Multifocal electroretinography of proband 3 demonstrates attenuation of amplitude and latency delay most prominent in the central macula, with relative sparing of the periphery.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Summary of Clinical Findings in 3 Families of Patients With the Glu292Lys BEST1Variation

References

Petrukhin  KKoisti  MJBakall  B  et al.  Identification of the gene responsible for Best macular dystrophy. Nat Genet 1998;19 (3) 241- 247
PubMed Link to Article
Marquardt  AStöhr  HPassmore  LAKrämer  FRivera  AWeber  BH Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). Hum Mol Genet 1998;7 (9) 1517- 1525
PubMed Link to Article
Marmorstein  ADMarmorstein  LYRayborn  MWang  XHollyfield  JGPetrukhin  K Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2000;97 (23) 12758- 12763
PubMed Link to Article
Sun  HTsunenari  TYau  KWNathans  J The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A 2002;99 (6) 4008- 4013
PubMed Link to Article
Tsunenari  TSun  HWilliams  J  et al.  Structure-function analysis of the bestrophin family of anion channels. J Biol Chem 2003;278 (42) 41114- 41125
PubMed Link to Article
Marmorstein  LYWu  JMcLaughlin  P  et al.  The light peak of the electroretinogram is dependent on voltage-gated calcium channels and antagonized by bestrophin (best-1). J Gen Physiol 2006;127 (5) 577- 589
PubMed Link to Article
Rosenthal  RBakall  BKinnick  T  et al.  Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J 2006;20 (1) 178- 180
PubMed
Yu  KXiao  QCui  GLee  AHartzell  HC The best disease-linked Cl- channel hBest1 regulates Ca V 1 (L-type) Ca2+ channels via src-homology-binding domains. J Neurosci 2008;28 (22) 5660- 5670
PubMed Link to Article
Deutman  AF Electro-oculography in families with vitelliform dystrophy of the fovea: detection of the carrier state. Arch Ophthalmol 1969;81 (3) 305- 316
PubMed Link to Article
Krill  AEMorse  PAPotts  AMKlien  BA Hereditary vitelliruptive macular degeneration. Am J Ophthalmol 1966;61 (6) 1405- 1415
PubMed
Miller  SABresnick  GHChandra  SR Choroidal neovascular membrane in Best's vitelliform macular dystrophy. Am J Ophthalmol 1976;82 (2) 252- 255
PubMed
Mohler  CWFine  SL Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology 1981;88 (7) 688- 692
PubMed Link to Article
Fishman  GABaca  WAlexander  KRDerlacki  DJGlenn  AMViana  M Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology 1993;100 (11) 1665- 1670
PubMed Link to Article
Chung  MMOh  KTStreb  LMKimura  AEStone  EM Visual outcome following subretinal hemorrhage in Best disease. Retina 2001;21 (6) 575- 580
PubMed Link to Article
Frangieh  GTGreen  WRFine  SL A histopathologic study of Best's macular dystrophy. Arch Ophthalmol 1982;100 (7) 1115- 1121
PubMed Link to Article
O'Gorman  SFlaherty  WAFishman  GABerson  EL Histopathologic findings in Best's vitelliform macular dystrophy. Arch Ophthalmol 1988;106 (9) 1261- 1268
PubMed Link to Article
Weingeist  TAKobrin  JLWatzke  RC Histopathology of Best's macular dystrophy. Arch Ophthalmol 1982;100 (7) 1108- 1114
PubMed Link to Article
Bakall  BRadu  RAStanton  JB  et al.  Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res 2007;85 (1) 34- 43
PubMed Link to Article
Mullins  RFKuehn  MHFaidley  EASyed  NAStone  EM Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease. Invest Ophthalmol Vis Sci 2007;48 (7) 3372- 3380
PubMed Link to Article
Mullins  RFOh  KTHeffron  EHageman  GSStone  EM Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. Arch Ophthalmol 2005;123 (11) 1588- 1594
PubMed Link to Article
Pianta  MJAleman  TSCideciyan  AV  et al.  In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 2003;76 (2) 203- 211
PubMed Link to Article
Renner  ABTillack  HKraus  H  et al.  Late onset is common in best macular dystrophy associated with VMD2 gene mutations. Ophthalmology 2005;112 (4) 586- 592
PubMed Link to Article
von Rückmann  AFitzke  FWBird  AC In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol 1997;115 (5) 609- 615
PubMed Link to Article
Bakall  BMarknell  TIngvast  S  et al.  The mutation spectrum of the bestrophin protein: functional implications. Hum Genet 1999;104 (5) 383- 389
PubMed Link to Article
Caldwell  GMKakuk  LEGriesinger  IB  et al.  Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. Genomics 1999;58 (1) 98- 101
PubMed Link to Article
Eksandh  LBakall  BBauer  BWadelius  CAndréasson  S Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene. Ophthalmic Genet 2001;22 (2) 107- 115
PubMed Link to Article
Marchant  DYu  KBigot  K  et al.  New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. J Med Genet 2007;44 (3) e70
PubMed Link to Article
Wabbels  BPreising  MNKretschmann  UDemmler  ALorenz  B Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 2006;244 (11) 1453- 1466
PubMed Link to Article
Apushkin  MAFishman  GATaylor  CMStone  EM Novel de novo mutation in a patient with Best macular dystrophy. Arch Ophthalmol 2006;124 (6) 887- 889
PubMed Link to Article
Krämer  FMohr  NKellner  URudolph  GWeber  BH Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD). Hum Mutat 2003;22 (5) 418
PubMed Link to Article
Krämer  FWhite  KPauleikhoff  D  et al.  Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet 2000;8 (4) 286- 292
PubMed Link to Article
Li  YWang  GDong  B  et al.  A novel mutation of the VMD2 Gene in a Chinese family with best vitelliform macular dystrophy. Ann Acad Med Singapore 2006;35 (6) 408- 410
PubMed
Marchant  DGogat  KBoutboul  S  et al.  Identification of novel VMD2 gene mutations in patients with best vitelliform macular dystrophy. Hum Mutat 2001;17 (3) 235
PubMed Link to Article
Seddon  JMSharma  SChong  SHutchinson  AAllikmets  RAdelman  RA Phenotype and genotype correlations in two best families. Ophthalmology 2003;110 (9) 1724- 1731
PubMed Link to Article
Sodi  APasserini  ISimonelli  FTesta  FMenchini  UTorricelli  F A novel mutation in the VMD2 gene in an Italian family with Best maculopathy. J Fr Ophtalmol 2007;30 (6) 616- 620
PubMed Link to Article
White  KMarquardt  AWeber  BH VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies. Hum Mutat 2000;15 (4) 301- 308
PubMed Link to Article
Palomba  GRozzo  CAngius  APierrottet  COOrzalesi  NPirastu  M A novel spontaneous missense mutation in VMD2 gene is a cause of a best macular dystrophy sporadic case. Am J Ophthalmol 2000;129 (2) 260- 262
PubMed Link to Article
Schatz  PKlar  JAndréasson  SPonjavic  VDahl  N Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet 2006;27 (2) 51- 56
PubMed Link to Article
Lotery  AJMunier  FLFishman  GA  et al.  Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41 (6) 1291- 1296
PubMed
Marchant  DGogat  KDureau  P  et al.  Use of denaturing HPLC and automated sequencing to screen the VMD2 gene for mutations associated with Best's vitelliform macular dystrophy. Ophthalmic Genet 2002;23 (3) 167- 174
PubMed Link to Article
Duncan  JLZhang  YGandhi  J  et al.  High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci 2007;48 (7) 3283- 3291
PubMed Link to Article
Spaide  RF Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110 (2) 392- 399
PubMed Link to Article
Marmor  MFZrenner  EInternational Society for Clinical Electrophysiology of Vision, Standard for clinical electro-oculography. Arch Ophthalmol 1993;111 (5) 601- 604
PubMed Link to Article
Marmor  MFZrenner  EInternational Society for Clinical Electrophysiology of Vision, Standard for clinical electroretinography (1999 update). Doc Ophthalmol 1998-1999;97 (2) 143- 156
PubMed Link to Article
Marmor  MFHood  DCKeating  DKondo  MSeeliger  MWMiyake  YInternational Society for Clinical Electrophysiology of Vision, Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 2003;106 (2) 105- 115
PubMed Link to Article
Weleber  RG Fast and slow oscillations of the electro-oculogram in Best's macular dystrophy and retinitis pigmentosa. Arch Ophthalmol 1989;107 (4) 530- 537
PubMed Link to Article
Marmorstein  ADStanton  JBYocom  J  et al.  A model of best vitelliform macular dystrophy in rats. Invest Ophthalmol Vis Sci 2004;45 (10) 3733- 3739
PubMed Link to Article
Stöhr  HMarquardt  ANanda  ISchmid  MWeber  BH Three novel human VMD2-like genes are members of the evolutionary highly conserved RFP-TM family. Eur J Hum Genet 2002;10 (4) 281- 284
PubMed Link to Article
Bard  LACross  HE Genetic counseling of families with Best macular dystrophy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1975;79 (6) OP865- OP873
PubMed
Yardley  JLeroy  BPHart-Holden  N  et al.  Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci 2004;45 (10) 3683- 3689
PubMed Link to Article
Burgess  RMillar  IDLeroy  BP  et al.  Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008;82 (1) 19- 31
PubMed Link to Article
Esumi  NKachi  SCampochiaro  PAZack  DJ VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. J Biol Chem 2007;282 (3) 1838- 1850
PubMed Link to Article
Esumi  NOshima  YLi  YCampochiaro  PAZack  DJ Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 2004;279 (18) 19064- 19073
PubMed Link to Article
Guziewicz  KEZangerl  BLindauer  SJ  et al.  Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci 2007;48 (5) 1959- 1967
PubMed Link to Article
Querques  GRegenbogen  MQuijano  CDelphin  NSoubrane  GSouied  EH High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol 2008;146 (4) 501- 507
PubMed Link to Article
Spaide  RFNoble  KMorgan  AFreund  KB Vitelliform macular dystrophy. Ophthalmology 2006;113 (8) 1392- 1400
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 10

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles